Skip to main content
Figure 4 | Genetic Vaccines and Therapy

Figure 4

From: A trial of somatic gene targeting in vivo with an adenovirus vector

Figure 4

Restriction analysis of the lacZ -negative gene from mice treated with a recombinant adenovirus. (A) AdNY57-injected mouse. The PCR product of the lambda bacteriophage DNA with primers that flank the target site is 288 bp long. The wild-type PCR product is cut with TfiI into 84 and 204 bp fragments, whereas the Glu461Ala mutant PCR product is not cut. Lane M: Marker DNA prepared by HinfI digestion of the plasmid pUC19; 1–12, lacZ-negative bacteriophages from animal number 2; lacZ+: Lambda bacteriophage recovered from control mouse; lacZ-Glu461Gly: lambda bacteriophage LIA15. (B) AdNY58-injected mouse. The PCR product of the lambda bacteriophage DNA with primers that flank the target site is 213 bp long. The Tyr105Stop mutant PCR product is cut with XspI into 146 and 67 bp fragments, whereas the wild-type product is not. Lane M: Marker DNA prepared by HinfI digestion of plasmid pUC19; 1–4, lacZ-negative bacteriophages from animal number 3; lacZ+: Lambda bacteriophage recovered from control mouse; lacZ-Tyr105Stop: lambda bacteriophage LIA11.

Back to article page